

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,  
South City 1, Sector – 41, Gurgaon,  
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

**Emergency : 105010**

Email : [secretarial@fortishealthcare.com](mailto:secretarial@fortishealthcare.com)

Website : [www.fortishealthcare.com](http://www.fortishealthcare.com)

FHL/SEC/2021-22

April 16, 2021

**The National Stock Exchange of India Ltd.**  
**Corporate Communications Department**  
**“Exchange Plaza”, 5<sup>th</sup> Floor, Bandra-Kurla**  
**Complex, Bandra (East), Mumbai – 400051**  
**Scrip Symbol: FORTIS**

**BSE Limited**  
**Corporate Services Department**  
**Phiroze Jeejeebhoy Towers**  
**Dalal Street, Mumbai – 400 001**  
**Scrip Code:532843**

**Sub: Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

Dear Sir(s),

This is in continuation of our intimation dated October 18, 2018, December 22, 2018, March 20, 2019 November 13, 2020 and November 21, 2020 with respect to an ad-interim ex-parte order passed by Securities and Exchange Board of India (“SEBI”) in the matter relating to the alleged diversion of funds from the Company by its erstwhile promoters. SEBI has issued a notice under Rule 4 of SEBI (Procedure for holding inquiry and imposing penalties) Rules, 1995 read with Section 15-I of Securities and Exchange Board of India Act, 1992 in the matter of Fortis Healthcare Limited to, among others, Escorts Heart Institute and Research Center Limited (EHIRCL), a wholly owned subsidiary of the Company. The notice was received by EHIRCL on April 15, 2021. The management and Board of the Company that was newly constituted after NTK Ventures Pte. Ltd. (a wholly owned subsidiary of IHH Healthcare Berhad) became promoters of the Company, are evaluating the notice received by EHIRCL, in consultation with its legal advisors.

The disclosure as required under Regulation 30 is enclosed as ‘Annexure-A’.

This is for your information and records please.

Thanking you,  
Yours faithfully,  
For **Fortis Healthcare Limited**

**Sumit Goel**  
**Company Secretary**  
**M. No. – F6661**

**Annexure A**  
**Disclosures as required under Regulation 30**  
**of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

<b>Regulatory action(s) with impact</b>		
<b>Sn.</b>	<b>Particulars</b>	<b>Details</b>
<b>1.</b>	The details of any change in the status and / or any development in relation to such proceedings	In the matter relating to the alleged diversion of funds from the Company by its erstwhile promoters, SEBI has issued a show cause notice to EHIRCL under Rule 4 of SEBI (Procedure for holding inquiry and imposing penalties) Rules, 1995 read with Section 15-I, Section 15HA and Section 15HB of Securities and Exchange Board of India Act, 1992.
<b>2.</b>	In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings	Not Applicable
<b>3.</b>	In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity	Not Applicable